-
IVIG is safe and effective for worsening MG, but has no effect on the natural course of Miller Fisher syndrome.
-
These 2 clinical trials comparing Standard and New Antiepileptic Drugs (SANAD) showed that for partial epilepsy, lamotrigine was clinically better than carbamazepine, and that for generalized and unclassifiable epilepsy, valproate was better tolerated than topiramate and more efficacious than lamotrigine.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
-
In addition to previously identified antibodies that cause limbic encephalitis, novel antibodies directed against cell membrane antigens may cause many of the "antibody-negative" cases, and these cases seem to respond favorably to immunosuppressive treatment.
-
Although spontaneous intracranial hypotension (SIH) generally causes a benign, self-limited, postural headache, subdural hematomas may occur in SIH with serious sequelae.
-
Compared with a lower dose, intensive treatment with atorvastatin in patients with stable coronary disease significantly reduces hospitalizations for HF.
-
Current AP schedules do not appear to prevent catheter-related thrombosis. Systemic VTE and mortality, however, appeared lower after prophylaxis.
-
Elimination of daily routine CXRs reduced the number of CXRs in a mixed medical-surgical ICU, while not affecting readmission rate and ICU and hospital mortality rates.
-
Obesity and the magnitude of nocturnal oxygen desaturation, which is an important pathophysiological consequence of OSA, are independent risk factors for incident AF in individuals <65 years of age.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.